Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-08-12
2008-12-16
Wilson, James (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S293000, C544S360000, C544S374000, C546S083000, C546S089000
Reexamination Certificate
active
07465741
ABSTRACT:
The invention concerns substituted tricyclic isoxazoline derivatives according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular tricyclic dihydrobenzopyranoisoxazoline, dihydroquinolinoisoxazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on the phenylpart of the tricyclic moiety with at least one radical that is attached to the phenyl radical by a carbon-carbon bond as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherin all variables are defined in claim1. (I) The compounds have surprisingly been shown to have selective serotonine (5-HT) reuptake inhibitor activity in combination with additional α2-adrenocptor antagonist activity and show a strong antidepressant and/or anxiolytic activity and/or antipsychotic and/or a body weight control activity without being sedative. Also, in view of their selective serotonine (5-HT) reuptake inhibitor as well as α2-adrenoceptor antagonist activity, compounds according to the invention are also suitable for treatment and/or prophylaxis in diseases where either one of the activities alone or the combination of said activities may be of therapeutic use.
REFERENCES:
patent: 7169786 (2007-01-01), Andres-Gil et al.
patent: 2005/0222125 (2005-10-01), Andres-Gil et al.
patent: 2006/0122167 (2006-06-01), Andres-Gil et al.
patent: 0885883 (1998-12-01), None
patent: WO 95/07893 (1995-03-01), None
patent: WO 97/25317 (1997-07-01), None
patent: WO 02/066484 (2002-08-01), None
patent: WO 03/082878 (2003-10-01), None
International Search Report for PCT/EP03/50374 dated Nov. 28, 2003.
Andres, J. Ignacio et al., “Synhesis of 3a,4-Dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, Displaying Combined 5-HT Uptake Inhibiting and α2-Adrenoceptor Anagonistic Activities: A Novel Series of Potential Antidepressants,” Bioorganic & Medicinal Chemistry Letter 13 (2003) 2719-2725.
Eichinger, Karl et al., “A Convenient Synthesis of 3-and 3,4-Substituted 4,5-Dihydroisoxazole-5-acetic Acids,” Synthetic Communications, 27(16), 2733-2742 (1997).
Alvarez-Escobar Rosa Maria
Andrés-Gil José Ignacio
Bakker Margaretha Henrica Maria
Bartolomé-Nebreda José Manuel
Megens Antonius Adrianus Hendrikus Petrus
Janssen Pharmaceutica N.V.
Leeser Erich A
Wilson James
Woodcock & Washburn LLP
LandOfFree
C-substituted tricyclic isoxazoline derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-substituted tricyclic isoxazoline derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-substituted tricyclic isoxazoline derivatives and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042057